Sökning: onr:"swepub:oai:DiVA.org:uu-204091" >
Projected cost-effe...
Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program
-
- Ostensson, Ellinor (författare)
- Karolinska Institutet
-
- Hellstrom, Ann-Cathrin (författare)
- Karolinska Institutet
-
- Hellman, Kristina (författare)
- Karolinska Institutet
-
visa fler...
-
- Gustavsson, Inger (författare)
- Uppsala universitet,Genomik
-
- Gyllensten, Ulf (författare)
- Uppsala universitet,Genomik
-
- Wilander, Erik (författare)
- Uppsala universitet,Obstetrik & gynekologi
-
- Zethraeus, Niklas (författare)
- Karolinska Institutet
-
- Andersson, Sonia (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2013-04-22
- 2013
- Engelska.
-
Ingår i: Acta Obstetricia et Gynecologica Scandinavica. - : Wiley. - 0001-6349 .- 1600-0412. ; 92:7, s. 830-840
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Human papillomavirus (HPV) testing is not currently used in primary cervical cancer screening in Sweden, and corresponding cost-effectiveness is unclear. Objective From a societal perspective, to evaluate the cost-effectiveness of high-risk (HR)-HPV testing using self-collected vaginal samples. Design A cost-effectiveness analysis. Setting The Swedish organized cervical cancer screening program. Methods We constructed a model to simulate the natural history of cervical cancer using Swedish data on cervical cancer risk. For the base-case analysis we evaluated two screening strategies with different screening intervals: (i) cytology screening throughout the woman's lifetime (i.e. conventional cytology strategy) and (ii) conventional cytology screening until age 35years, followed by HR-HPV testing using self-collected vaginal samples in women aged 35years (i.e. combination strategy). Sensitivity analyses were performed, varying model parameters over a significant range of values to identify cost-effective screening strategies. Main outcome measures Average lifetime cost, discounted and undiscounted life-years gained, reduction in cervical cancer risk, incremental cost-effectiveness ratios with and without the cost of added life-years. Results Depending on screening interval, the incremental cost-effectiveness ratios for the combination strategy ranged from Euro43000 to Euro180000 per life-years gained without the cost of added life-years, and from Euro74000 to Euro206000 with costs of added life-years included. Conclusion The combination strategy with a 5-year screening interval is potentially cost-effective compared with no screening, and with current screening practice when using a threshold value of Euro80000 per life-years gained.
Nyckelord
- Cervical cancer
- cost-effectiveness
- human papillomavirus (HPV)
- screening
- self-sampling
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas